A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
AIMS: To evaluate whether weight-loss interventions are associated with obesity-associated cancers (OAC) in individuals with overweight/obesity and type 2 diabetes (T2D). MATERIALS AND METHODS: This retrospective cohort study utilised the TriNetX fed…
BACKGROUND: GLP-1 analogues are a relatively new class of medications that form the cornerstone of diabetes treatment. They possess invaluable glucose-lowering properties without hypoglycemic effects as well as strong cardioprotective effects. The gu…
BACKGROUND: Treatment of type 2 diabetes mellitus (T2DM) relies on diverse glucose-lowering medications, championing sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists as viable options to address concurr…
OBJECTIVE: To evaluate the efficacy, safety, and clinical implications of insulin icodec, a novel once-weekly basal insulin for the treatment of type 1 diabetes (T1D) and type 2 diabetes (T2D), with an emphasis on its advantages and challenges in com…
Diabetic cardiomyopathy causes end-stage heart failure, resulting in high morbidity and mortality in type 2 diabetes mellitus (T2DM) patients. Long-term treatment targeting metabolism is an emerging field in the treatment of diabetic cardiomyopathy.…
The weight of the matter in diabetes care challenges the traditional glucose-centric model of diabetes management and argues for a paradigm shift toward prioritizing weight-specifically fat reduction-as the central lever in achieving metabolic health…
INTRODUCTION: Semaglutide 2.4 mg (Wegovy) is the first second-generation anti-obesity medication approved by the FDA for long-term obesity treatment. Given the effectiveness of semaglutide 2.4 mg compared to first-generation anti-obesity medications…
IMPORTANCE: Recent studies have suggested an association between nonarteritic anterior ischemic optic neuropathy (NAION) with semaglutide usage. However, the limitations of those analyses warrant further investigation, given the frequency of use of t…
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely prescribed for their efficacy in glycemic control and weight reduction, but patient response is heterogeneous and predictors of weight loss remain insufficiently defined. T…
INTRODUCTION: Chronic Kidney Disease (CKD) affects 1 in 7 adults in the United States, yet 90% of those impacted remain unaware of their condition, and fewer than 20% of at-risk individuals are appropriately tested. Safety-net health care settings ar…
INTRODUCTION: Clinical trials have demonstrated greater glycemic control and weight loss with once-weekly (OW) semaglutide versus other anti-diabetes medications, including sodium-glucose co-transporter 2 inhibitors (SGLT2is) in adults with type 2 di…
High-fat diet (HFD)-induced microglial activation contributes to hypothalamic inflammation and obesity, but the mechanisms linking microglia to structural changes remain unclear. This study explored the role of microglia in impairing hypothalamic syn…
AIMS: Obesity and overweight pose significant global health challenges necessitating effective pharmacological interventions. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged for their weight-reducing effects in non-diabetic individ…
Anti-obesity medications (AOMs) have become one of the most prescribed drugs in human medicine. While AOMs are known to impact adult neurogenesis in the hypothalamus, their effects on the functional maturation of hypothalamic neurons remain unexplore…
OBJECTIVE: This study aimed to evaluate the weight loss efficacy of semaglutide initiated 6 months after laparoscopic sleeve gastrectomy (LSG). METHODS: This retrospective study included patients undergoing primary LSG. Patients receiving semaglutide…
INTRODUCTION: Clinical trials have shown efficacy of semaglutide for weight loss, but further study is needed in less controlled environments including impacts on body composition. MATERIALS AND METHODS: This retrospective study included individuals…
BACKGROUND: Spinal cord stimulation (SCS) is an effective treatment option for patients suffering from chronic intractable pain of the trunk and/or limbs. One of the potential adverse effects of SCS is discomfort or pain at the site of the implantabl…
The new European clinical practice guidelines from three scientific societies (European Association for the Study of the Liver, European Association for the Study of Diabetes and European Association for the Study of Obesity) on the management of met…